ASCO: AstraZeneca's Baselga on tailoring treatments and the march to cure cancer
fiercebiotech | June 04, 2019
AstraZeneca posted promising data for its AKT inhibitor capivasertib paired with the chemotherapy Faslodex in patients with ER-positive breast cancer. The combo staved off cancer for 10 months-double the time Faslodex plus placebo logged-and helped patients live a median of six months longer. The phase 2 data, presented Tuesday at the annual meeting of the American Society for Clinical Oncology, show that blocking AKT-a critical pathway that regulates estrogen receptor (ER) function-along with anti-estrogen therapy is resulting in improved outcomes in these patients,José Baselga, AstraZenecas oncology R&D chief, told FierceBiotech.